Par Pharmaceutical commences shipping sapropterin dihydrochloride tablets and powder for oral solution
2 October 2020 -

Par Pharmaceutical Inc, a subsidiary of Endo International plc (NASDAQ: ENDP), has started shipping sapropterin dihydrochloride tablets, 100mg, and powder for oral solution, 100mg and 500mg, it was reported on Thursday.

The company has launched the product following final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application.

The products are the generic version of Kuvan tablets and powder for oral solution and are the first, and presently the only, generic versions available.



Related Headlines